News and press
Focus successful in UK litigation against Novartis concerning Voleze® Rivastigmine Transdermal Patches
- Focus delivers niche branded and generic products to the UK market to generate sustainable income streams that can be reinvested in new product development
- Focus aims to maintain its double digit growth through the introduction of at least five new products each year
- Focus dedicates almost half its annual expenditure year on year to developing new generic products for the UK market
- Focus aims to give its customers choices and alternatives in the prescription only medicines market that other companies do not offer.